Oramed receives $13M from Scilex in first tranche of warrant repurchase

ORAMED PHARMACEUTICALS INC.

Scilex repurchased warrants for 3,130,000 shares of Scilex common stock for $13,000,000 on Sept 30, 2025.
Scilex retains option to repurchase remaining 3,370,000 warrants for $14,000,000 by Dec 31, 2025.
Total aggregate purchase price for both tranches is $27,000,000; original option agreement was filed July 23, 2025.
Warrants repurchased have an exercise price of $0.01 per share of Scilex common stock.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.